- Akeso (SEHK:9926) received regulatory approval in China for ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non small cell lung cancer.
- The decision establishes ivonescimab combination therapy as a new standard of care for this patient group in China.
- The approval follows Phase III data that were presented at ASCO and published in The Lancet, which underscores international clinical recognition.
For investors tracking how new oncology drugs and clinical data are reshaping treatment standards, the wider move toward AI supported healthcare platforms is also worth a closer look through 133 healthcare AI stocks.
Akeso is a biopharmaceutical company based in Hong Kong that focuses on researching, developing, manufacturing, and commercializing antibody drugs worldwide. The new lung cancer indication adds to its position as a specialist in complex biologic treatments within the biotech sector.
Beyond the headline: 0 risks and 2 things going right for Akeso that every investor should see.
How does this approval change ivonescimab’s position in lung cancer?
The NMPA decision gives Akeso a third lung cancer indication for ivonescimab and positions the ivonescimab plus chemotherapy regimen as the new first line standard for advanced squamous NSCLC in China. For investors, that strengthens the drug’s role as a core asset in Akeso’s immuno oncology 2.0 story.
What does the clinical data signal about Akeso’s competitive footing?
In HARMONi-6, ivonescimab plus chemotherapy delivered median PFS of 11.1 months versus 6.9 months for tislelizumab plus chemotherapy, with a hazard ratio of 0.60. The Plenary Session slot at ASCO 2026 and twin publications in The Lancet highlight that peers and clinicians are treating these results as globally relevant, not just local.
What should investors watch next to see if this approval really moves the needle for Akeso?
The key test is how rapidly ivonescimab combination therapy is adopted into routine first line care in China and whether that supports broader use across Akeso’s IO2.0 plus ADC2.0 programs in breast and other solid tumors. Concrete signals include future disclosure on treated patient numbers, reimbursement progress and readouts from ongoing Phase II and Phase III trials that use ivonescimab as a backbone.
For the full picture including more risks and rewards, check out the complete Akeso analysis.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com